Engineered immune cells take on multiple metastatic cancers
NCT ID NCT05296564
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 25 times
Summary
This early-phase study tests a treatment where a patient's own immune cells are modified in a lab to better recognize and attack cancer cells that carry a specific marker called NY-ESO-1. The therapy is given as a one-time infusion to adults with advanced or spreading cancers like sarcoma, melanoma, or lung cancer that have not responded to standard treatments. The main goals are to check safety and see if tumors shrink.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hadassah Medical Organization
RECRUITINGJerusalem, 9112001, Israel
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.